ProShares Ultra Nasdaq Biotechnology
NASDAQ · us_market
No AI summary generated yet for this ticker.
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
First quarter results point to sharpened sector divergence, separating AI-driven winners from those facing structural and geopolitical headwinds.
US growth stocks underperformed in early 2026 amid AI disruption fears and an unresolved conflict in the Middle East.
Active equity investors Carrie King and Erin Xie address key questions about healthcare stocks. Read more here.
Longevity, the length of human life, is the subject of growing scientific and commercial interest. Click here to read more.
The Trump administrationâs recent cuts at the FDA have put the agencyâs executive capacity under strain, which may lead to medicine shortages and less innovation.
While AI remains the dominant theme in corporate earnings, Morningstar Research's David Sekera says investors should keep in mind that not all tech stocks are created equal. Read more here.
Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic.
AI applications in healthcare have emerged across four key areas: prediction, diagnosis, treatment, and system efficiency. Read more here.
Survey data underscored how the war in the Middle East has already had a material impact on economic growth around the world. Read more here.
After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Read more here.
US launch of Operation Epic Fury against Iran in late February triggered the closure of the Strait of Hormuz, spiking energy prices and driving pressure on both equities and bonds.
The U.S. military campaign against the Iranian theocracy has roiled financial markets. As a result of the incursion, oil prices are surging and are up 90%+ since the beginning of the year.
After years of technology dominance, market leadership appears to be shifting; will it last? Click here to read more.
Mid-cap stocks can help investors diversify beyond big tech. Mid-caps in the healthcare space are benefitting from AI developments. Read more here.
Healthcare stocks were rattled by US policy uncertainty in 2025. But signs of resilience have surfaced as the sector reaffirms its defensive strengths and growth potential.
Direxion CURE ETF offers 3x daily healthcare exposureâlearn risks like volatility decay and drift, plus tactical trading tips using XLV/index signals.
Solid US economic growth and Federal Reserve rate cuts have boosted corporate earnings and profit margins, lifting US stocks and underpinning our overweight. Read more here...